Free beta access. 5 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

CEPI 2.0 key to solve

Richard Hatchett & Morrison, 6-29-2021, CEO of the Coalition for Epidemic Preparedness Innovation, CEPI & former BARDA, acting director U.S. Biomedical Advanced Research and Development Authority, & J. Stephen Morrison, senior vice president here at the Center for Strategic and International Studies, CSIS

https://www.csis.org/analysis/cepi-20-critical-inflection-point, "CEPI 2.0: A Critical Inflection Point," No Publication (ermo/sms, Acc:6-20-2022)

Richard Hatchett, M.D.: Well, CEPI 2.0 is actually about the opportunities that have been created by the response to the pandemic. And it—Julie, when you started and were talking about CEPI’s creation and the idea that it was founded because there was a realization that there weren’t technical barriers or scientific barriers necessarily but there were funding barriers and there was an absence of political will. And I think we’re kind of in the same situation with respect to pandemic risk, in that we’re going to emerge from this pandemic with a whole suite of new tools and new technology platforms that have been validated and that have demonstrated that, you know, rapid vaccine development is possible.

And we actually know what we need to do to, you know, vastly improve the world’s preparedness for future pandemics, or even—I mean, vastly reduce the risk, or even potentially, you know, take pandemics off the table. I don’t think that’s as far-fetched as it might sound. And so what CEPI 2.0 is, or what we’ve put forward is a, you know, a proposal for the world. And then within that, CEPI has a role. And we’ve sketched out what we would do with, you know, if we were able to secure the resources.

And the $3.5 billion that we have talked about wouldn’t deliver, you know, a pandemic-free world. But what we think would, you know, what we think the world should do, if it can muster its political will, if it can muster the resources even in the midst of fighting the current pandemic but looking forward and take advantage of the opportunity, I mean, we think that we obviously need to finish the job on Covid. We need the generation 2.0 vaccines, and even generation 3.0—the oral vaccines and the mucosal vaccines.

We need to do everything that we can to take coronaviruses off the table. They are now—if anybody ever needed to argue that they were a pandemic threat before, we know they’re a pandemic threat now. And we know there are other coronaviruses out there. Looking at our experience, we broke every speed record in the development of vaccines for Covid, and it wasn’t fast enough. We need to dramatically shorten vaccine development times. And—

J. Stephen Morrison: This is where you get to your moonshot.

Richard Hatchett, M.D.: This is where you get to the 100-day goal. And then we need to break that down. I mean, we don’t just throw that out as an aspiration. We have to actually have an idea of how we go about doing that. And we’re looking at every step of vaccine development to think where we can achieve time savings. One of the most important places that we can achieve time savings is by being at least as prepared for future threats as we were actually prepared for Covid.

And that preparedness for Covid was based on concerns about coronaviruses and based on investments on understanding how to develop vaccines against SARS and MERS. And those investments paid off in spades during the response. And it essentially allowed new vaccines, which have now been shown to be 94-95 percent effective, to be designed, and I’m not speaking hyperbolically, literally within hours of getting the sequences. And we need to do all of this, you know, while laying the foundations for equity and leaving no one behind.

And so CEPI, in mapping out the 2.0 agenda, those are sort of the core components of the agenda. And it’s a shared agenda. It’s not something that CEPI’s going to own and go off and do by itself. It’s a proposal that we brought to the world, and which has been embraced by, you mentioned the United Kingdom. They’ve become a huge supporter of our efforts. And they have taken that core moonshot idea of the—

J. Stephen Morrison: And embraced it.

Richard Hatchett, M.D.: Embraced it. Took it to the G7, who welcomed it. And now we’re talking with the U.K., with the U.S., with other partners about how do we, you know, collectively, collaboratively, you know, bring that vision to pass?

Sign in to recut, update, or save this card.